$CLOV

Reynoso Jamie L. sold $61K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 13,119 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Jul 16, 2026, 8:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale of 13,119 shares at $4.6700 on 2026-07-15, filed on 2026-07-16, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider activity, but the 10b5-1 designation and modest transaction value suggest limited incremental trading edge.

03

What to watch

Form 4s often do not capture the full context of insider compensation, tax planning, or concurrent option exercises; the article provides only the sale details.

Relevance 2/10Novelty 3/10Timing: latest Form 4 filed 2026-07-16, covering a sale executed 2026-07-15

Background

The article is a SEC Form 4 insider transaction disclosure for Clover Health Investments Corp. (CLOV).

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health CEO Jamie Reynoso sold 13,119 shares on 2026-07-15 at $4.6700, totaling about $61.3K, under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, but the article specifies a pre-arranged 10b5-1 plan and the disclosed sale size is modest relative to typical market moves.

Market effects

No clear sector read-through from a single, modest 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

The sale could reflect diversification or liquidity needs rather than bearish expectations, especially given the explicit 10b5-1 plan.

Key entities

  • CLOV

    Clover Health Investments Corp. (issuer of the Form 4).

  • Jamie L. Reynoso

    CEO, Medicare Advantage, who executed the reported open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLOVHigh

Why is Clover Health stock climbing 4% today?

Clover Health (CLOV) stock rose 4.3% in pre-market trading after Needham initiated coverage with a Buy rating and $6.00 price target, citing its Medicare Advantage rating and cohort economics. The company's upcoming conference presentation and Q3 earnings report also contributed to the positive sentiment. The Nasdaq Composite was up 0.5% in pre-market.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$CLOVHigh

Why Is Clover Health (CLOV) Stock Soaring Today

Clover Health (CLOV) stock rose 10.7% premarket after CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The ratings, excluding disputed measures, boost payments and enrollment. Shares later cooled to $4.81, up 5%. CLOV is up 99.5% YTD but still below its 52-week high.

$CLOVMed

Is Clover Health Stock Too Dependent On One Group Of Members?

Clover Health Investments (CLOV) reported that nearly half of its Medicare Advantage members joined in 2025 or 2026, impacting short-term profits. Membership grew 48% YoY to 157,000, with new members accounting for 49%. Despite a 70% stock return over 12 months, CLOV's revenue declined 0.7%, and gross profit grew slower than revenue. Management raised full-year guidance but cautioned about future trends.

$CLOVMed

Clover Health Medicare Advantage PPO Plans Earn 5-Star Rating; HMO at 4.5 Stars

Clover Health's PPO Medicare Advantage plans received a 5.0 Star rating and HMO plans 4.5 Stars for 2027, impacting 2028 payments. CMS removed 20 measures for PPO plans, raising their rating. Clover's MA membership grew ~48% YoY to >157,000 members, with 98% in PPO plans. The company ranked #1 among non-SNP PPO plans with >2,000 members on core HEDIS measures, scoring 4.82 out of 5.